Rani Therapeutics Holdings Inc (RANI) USD0.0001 A

Sell:$1.08Buy:$1.12No change

Prices delayed by at least 15 minutes
Sell:$1.08
Buy:$1.12
Change:No change
Prices delayed by at least 15 minutes
Sell:$1.08
Buy:$1.12
Change:No change
Prices delayed by at least 15 minutes

Company Information

About this company

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).

Key people

Mir Imran
Executive Chairman of the Board
Talat Imran
Chief Executive Officer, Director
Svai S. Sanford
Chief Financial Officer
Mir Hashim
Chief Scientific Officer
Eric Groen
General Counsel
Kate Mckinley
Chief Business Officer
Laureen Debuono
Lead Independent Director
Andrew Farquharson
Director
Dennis A. Ausiello
Independent Director
Jean-Luc Butel
Independent Director
Maulik Nanavaty
Independent Director
Click to see more

Key facts

  • EPIC
    RANI
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US7530181004
  • Market cap
    $66.17m
  • Employees
    105
  • Shares in issue
    33.57m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.